Trials / Completed
CompletedNCT01535950
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LFG316 | |
| DRUG | Placebo | Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle. |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2012-02-20
- Last updated
- 2020-12-19
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01535950. Inclusion in this directory is not an endorsement.